Table 2

Primary outcomes of treatment at months 6 and 12 of the study

VariablesNoPer centNoPer centPer cent(95% CI)p Value% (95% CI)p Value
Complete remission
At 6th month7/2528.003/2512.0016.00(−5.7 to 37.7)0.1511.2 (−12.1 to 34.6)0.35
At 12th month9/2536.007/2429.176.83(−19.3 to 33.0)0.61−5.12 (−32.7 to 22.5)0.72
Partial remission
At 6th month8/2532.0012/2548.00−16.00(−42.8 to 10.8)0.24−12.61 (−41.6 to 16.3)0.39
At 12th month8/2532.0010/2441.67−9.67(−34.6 to 17.2)0.48−12.04 (−40.0 to 15.9)0.40
Non-remission
At 6th month10/2540.0010/2540.000.00(−27.2 to 27.2)1.00−1.20 (−30.6 to 28.3)0.94
At 12th month8/2532.007/2429.172.83(−23.0 to 28.6)0.8311.40 (−14.4 to 37.1)0.39
Discontinuation‡
0–6th month7/3221.882/277.4114.47(−2.9 to 31.9)0.1016.90 (1.3 to 32.4)0.03
7–12th month0/250.001/254.00−4.00(−11.7 to 3.7)0.31−0.40 (−11.5 to 3.5)0.30
0–12th month7/3221.883/2711.110.76(−7.8 to 29.4)0.2614.11 (−3.1 to 31.3)0.11
Composite outcome§
0–6th month17/3253.1312/2744.448.68(−16.8 to 34.2)0.5110.68 (−15.7 to 37.1)0.43
7–12th month8/2532.008/2532.000.00(−25.9 to 25.9)1.006.31 (−20.4 to 33.0)0.64
0–12th month15/3246.8810/2737.049.84(−15.3 to 35.0)0.4412.8 (−11.8 to 37.4)0.31
• *The difference is shown as the value for group 1 minus the value for group 2.

• †Adjusted for baseline nephrotic-range proteinuria and estimated glomerular filtration rates.

• ‡Including either death, major infection, doubling of serum creatinine or loss of follow-up.

• §Including either death, doubling of serum creatinine, non-remission or intolerance to treatment.

• CYC, cyclophosphamide; EC-MPS, enteric-coated mycophenolate sodium.